Clinical Trial Update: Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of maraviroc in HIV-1–exposed infants at risk of acquiring HIV-1 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-11-23